In a quiet week for approvals from the US Food and Drug Administration, Novartis AG’s slow-growing blockbuster heart drug Entresto gained an expanded indication in heart failure.
The FDA’s popular Real-Time Oncology Review (RTOR) pilot program grew by two after Seagen Inc. and Astellas Pharma,...